

## HR 1298

Orphan Drug Tax Credit Act of 2001

**Congress:** 107 (2001–2003, Ended)

**Chamber:** House

**Policy Area:** Taxation

**Introduced:** Mar 29, 2001

**Current Status:** Referred to the House Committee on Ways and Means.

**Latest Action:** Referred to the House Committee on Ways and Means. (Mar 29, 2001)

**Official Text:** <https://www.congress.gov/bill/107th-congress/house-bill/1298>

### Sponsor

**Name:** Rep. Brady, Kevin [R-TX-8]

**Party:** Republican • **State:** TX • **Chamber:** House

### Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Johnson, Nancy L. [R-CT-6]	R · CT		Mar 29, 2001
Rep. Price, David E. [D-NC-4]	D · NC		May 24, 2001
Rep. Ramstad, Jim [R-MN-3]	R · MN		Jun 26, 2001
Rep. Matsui, Robert T. [D-CA-5]	D · CA		Jul 11, 2001
Rep. Neal, Richard E. [D-MA-2]	D · MA		Jul 11, 2001

### Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Mar 29, 2001

### Subjects & Policy Tags

#### Policy Area:

Taxation

### Related Bills

*No related bills are listed.*

### Summary (as of Mar 29, 2001)

Orphan Drug Tax Credit Act of 2001 - Amends the Internal Revenue Code to move up the date for which a taxpayer may claim the credit for the clinical testing of drugs for rare diseases or conditions (orphan drugs) from the date a drug is designated an orphan drug to the date the application for such designation is filed.

## Actions Timeline

---

- **Mar 29, 2001:** Introduced in House
- **Mar 29, 2001:** Introduced in House
- **Mar 29, 2001:** Sponsor introductory remarks on measure. (CR E488)
- **Mar 29, 2001:** Referred to the House Committee on Ways and Means.